Developing new indications
for approved medicines in hematological malignancies
using a proprietary continuous delivery platform.

Targeted continuous delivery

We reimagine FDA-approved medicines and leverage our delivery system to establish new profiles. Our platform technology allows for lower drug exposure and the potential for improved efficacy.

Careers

We are building a team dedicated to delivering breakthrough, transformative products for patients with blood cancers. Learn more about career opportunities at Starton.

News and Events

September 14, 2020

Keith Darragh Joins Starton Therapeutics as Chief Financial Officer

NEW YORK, N.Y., September 14, 2020 – Starton Therapeutics Inc. (“Starton” or the “Company”), a clinical stage biotechnology powering continuous delivery of approved drugs for novel indications, announced today…

September 9, 2020

Drs. Kenneth Anderson and Asher Chanan-Khan to Join Starton Therapeutics Board of Directors 

NEW YORK, N.Y., September 9, 2020 – Starton Therapeutics Inc. (“Starton” or the “Company”), a clinical stage biotechnology company powering continuous delivery of approved drugs in novel indications, announced…